Brokerages Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $17.00

Inozyme Pharma, Inc. (NASDAQ:INZY) has received an average recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $17.25.

A number of analysts have recently weighed in on INZY shares. Wedbush reiterated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Raymond James started coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, HC Wainwright upped their price target on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday.

Inozyme Pharma Trading Down 28.6 %

INZY stock opened at $2.00 on Friday. Inozyme Pharma has a 52 week low of $1.97 and a 52 week high of $7.80. The company has a market capitalization of $128.48 million, a PE ratio of -1.28 and a beta of 1.35. The company’s 50-day simple moving average is $3.02 and its 200 day simple moving average is $4.38. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. As a group, sell-side analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Investors Weigh In On Inozyme Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of INZY. Deerfield Management Company L.P. Series C acquired a new stake in shares of Inozyme Pharma during the second quarter valued at about $52,000. Virtu Financial LLC acquired a new stake in Inozyme Pharma during the 3rd quarter worth approximately $64,000. Meeder Asset Management Inc. bought a new stake in Inozyme Pharma during the 2nd quarter worth approximately $68,000. SG Americas Securities LLC bought a new stake in Inozyme Pharma during the 3rd quarter worth approximately $81,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Inozyme Pharma in the 2nd quarter valued at approximately $84,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.